COGT Cogent Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1622229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-38.5%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.6%
ROA-64.8%
ROIC (approx.)-89.9%
Asset turnover—
Leverage & solvency
Liabilities / assets38.0%
Debt / equity0.43x
Current ratio10.99x
Interest coverage-85.23x
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-13.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $269.78M | $232.66M |
| SG&A expense | $63.58M | $43.28M |
| Operating income | -$333.36M | -$275.94M |
| Interest expense | $3.06M | — |
| Income tax | $0 | — |
| Net income | -$328.94M | -$255.86M |
| EBITDA | -$330.76M | -$273.44M |
| EPS (basic) | -2.16 | -1.94 |
| EPS (diluted) | -2.16 | -1.94 |
| Weighted avg. shares (diluted) | 128.90M | 103.86M |
| Balance sheet | ||
| Cash & equivalents | $312.01M | $98.17M |
| Short-term investments | $588.75M | $188.91M |
| Current assets | $910.36M | $296.47M |
| PP&E, net | $5.46M | $6.47M |
| Total assets | $937.61M | $327.90M |
| Current liabilities | $63.95M | $55.71M |
| Long-term debt | $222.90M | $0 |
| Total debt | $222.90M | $0 |
| Total liabilities | $301.24M | $71.61M |
| Shareholders' equity | $636.37M | $256.29M |
| Net debt | -$89.12M | -$98.17M |
| Shares outstanding | 160.98M | 110.46M |
| Cash flow statement | ||
| Operating cash flow | -$264.44M | -$207.79M |
| Capital expenditure | $1.55M | $573,000 |
| Free cash flow | -$266.00M | -$208.36M |
| Investing cash flow | -$399.53M | $38.28M |
| Financing cash flow | $878.23M | $214.45M |
| Depreciation & amortization | $2.60M | $2.50M |
| Stock-based compensation | $46.08M | $39.74M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.